synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-11. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Low genetic variation was found to occur between the three song characteristics in C. brunneus and C. jacobsi and no sex linkage was found. Peg numbers on the stridulatory file, while different between the two species, are surprisingly not dependent on song characteristics. Genetics cannot account for the difference in peg number. Instead additive effects explain the phenotypic variation in both song characteristics and peg number between C. brunneus, C. jacobsi, and their hybrids.
==== p53 regulation ==== Gene amplification often occur in various tumor cases, including of MDM2, a gene encodes for a RING E3 Ubiquitin ligase responsible for downregulation of p53 activity. MDM2 targets p53 for ubiquitylation and proteasomal degradation thus keeping its level appropriate for normal cell condition. Overexpression of MDM2 causes loss of p53 activity and therefore allowing cells to have a limitless replicative potential.
== History == Sauk City restaurateurs and husband and wife team George and Ruth Culver started their fast food careers as the owners of an A&W on Phillips Boulevard (U.S. Highway 12) in 1961. In 1968, they purchased a resort-styled restaurant at Devil's Lake called The Farm Kitchen. Their son, Craig Culver, worked for a local McDonald's right out of college in 1973. George, Ruth, their son Craig, and his wife Lea opened the first Culver's Frozen Custard and ButterBurgers in Sauk City, Wisconsin on July 18, 1984. Craig was CEO of Culver's from its inception until mid-2015.
Sources: en.wikipedia.org
The Census and Statistics Department estimated Hong Kong's population at 7,413,070 in 2021. The overwhelming majority (91.6%) is Chinese, most of whom are Taishanese, Teochew, Hakka, and other Cantonese peoples. The remaining 8.4% are non-ethnic Chinese minorities, primarily Filipinos, Indonesians, and South Asians. However, most Filipinos and Indonesians in Hong Kong are short-term workers. According to a 2021 thematic report by the Hong Kong government, after excluding foreign domestic helpers, the real number of non-Chinese ethnic minorities in the city was 301,344, or 4% of Hong Kong's population. About half the population have some form of British nationality, a legacy of colonial rule; 3.4 million residents have British National (Overseas) status, and 260,000 British citizens live in the territory. The vast majority also hold Chinese nationality, automatically granted to all ethnic Chinese residents at the handover. Headline population density exceeds 7,060 people/km2 It is the fourth-highest in the world.
=== Anti-corruption campaigns === Bukele established the International Commission Against Impunity in El Salvador (CICIES) in September 2019, an anti-corruption commission to combat drug trafficking, corruption, and white-collar crimes. CICIES was operated by the Salvadoran government and the Organization of American States (OAS), and cooperated with the National Civil Police to form an anti-corruption unit. Bukele dissolved CICIES in June 2021 after the OAS named Ernesto Muyshondt an anti-corruption advisor; Ernesto Muyshondt was accused by the Salvadoran government of electoral fraud and illegal negotiation with gang members to vote for ARENA during the 2014 presidential election. He was arrested and was scheduled to go on trial in April 2024, despite concerns about his health. On 1 June 2023, during a speech celebrating his fourth year in office, Bukele stated that his government would begin a "war against corruption" ("guerra contra la corrupción"). He announced that he would build a prison for individuals convicted of white-collar crimes that would be similar to the Terrorism Confinement Center. Bukele stated that the police and military would arrest white-collar criminals like they capture gang members in the gang crackdown. He added that Attorney General Rodolfo Delgado was in the process of raiding and confiscating assets worth up to $68 million from former Salvadoran president Alfredo Cristiani as part of the anti-corruption campaign.
== Development == A cooperative Half-Life game was first alluded to by publisher Sierra On-Line in November 2000 with the announcement of a PlayStation 2 version of Half-Life. At the time, however, it was unclear how a cooperative version of Half-Life would be implemented; the developers, Gearbox Software, were still experimenting with finding the most balanced number of players to build a cooperative game around. By E3 2001, the game had acquired the title Decay, named after the scientific concept of exponential decay for consistency with the scientific names used by previous Half-Life titles. While the E3 convention only provided a demonstration of the main Half-Life PlayStation 2 game, further details were released relating to Decay's premise and story, as well as confirming that the cooperative mode was to be designed for two players. The game's use of new model sets were also showcased. These new models were updated versions of Gearbox's High Definition pack for Blue Shift, featuring higher numbers of polygons and animation features such as facial expressions. The enhanced models were around twice as detailed as those in the High Definition pack, which itself was of a much higher quality than the original models in Half-Life. Media updates through the months following E3 showed various screenshots and the trailer to the game. On August 18, 2001, Sierra announced that Decay was nearly complete, and would be submitted to PlayStation 2 manufacturer Sony for verification within days.
The median age of menarche for a population may be an index of the proportion of undernourished females in the population, and the width of the spread may reflect unevenness of wealth and food distribution in a population. Researchers have identified an earlier age of the onset of puberty. However, they have based their conclusions on a comparison of data from 1999 with data from 1969. In the earlier example, the sample population was based on a small sample of white females (200, from Britain). The later study identified as puberty as occurring in 48% of African-American females by age nine, and 12% of white females by that age. One possible cause of a delay in the onset of puberty past the age 14 in females and 15 in males is Kallmann syndrome, a form of hypogonadotropic hypogonadism (HH). Kallmann syndrome is also associated with a lack of sense of smell (anosmia). Kallmann syndrome and other forms of HH affect both men and women. It is caused by a failure in HPG axis at puberty which results in low or zero gonadotropin (LH and FSH) levels with the subsequent result of a failure to commence or complete puberty, secondary hypogonadism and infertility.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.